TrialBlood advances2026
Venetoclax and ibrutinib induces durable clinical responses in marginal zone lymphoma.
Sasanka M Handunnetti et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
1 paper cites it
this papercites it
TrialBlood advances2026
Sasanka M Handunnetti et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.